Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

TD Cowen Maintains Outperform on NeoGenomics, Lowers Price Target to $19

Author: Benzinga Newsdesk | December 29, 2023 09:40am
TD Cowen analyst Dan Brennan maintains NeoGenomics (NASDAQ:NEO) with a Outperform and lowers the price target from $22 to $19.

Posted In: NEO

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist